Skip to main content
All lobbying filings

HOOPER, LUNDY & BOOKMAN, P.C.

HOOPER, LUNDY & BOOKMAN, P.C. filed a Q1 report for BRAINFUTURES on April 20, 2026, reporting $40,000 in lobbying income.

Lobbying for BRAINFUTURES · Nonprofit advocate for therapeutic treatments for mental health and substance use disorder

All filings by HOOPER, LUNDY & BOOKMAN, P.C. · Everything BRAINFUTURES has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Income
$40,000
What the client paid this registrant for the period.
Client based in
Maryland

Official filing document

 Lobbyists on this filing 1
  • LISA LAYMAN New on this filing
    Previously held: SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001- 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Health Issues

Issues related to a pathway for FDA approval of psychedelic drugs and therapies; issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; Public Law No: 119-26, related to implementation of research provisions.

Medical/Disease Research/Clinical Labs

Issues related to a pathway for FDA approval of psychedelic drugs and therapies; issues related to reducing barriers to research and increasing federal funding of clinical research trials for psychedelic drugs and therapies; issues related to medical adoption of and access to psychedelic drugs and therapies, including reimbursement and workforce; Public Law No: 119-26, related to implementation of research provisions.

Budget/Appropriations

H.R. 7148/Public Law No: 119-75, psychedelic therapies for treatment of mental health and substance use disorders related to the FY26 budget for the Department of Health and Human Services; FY2027 budget related to psychedelic therapies for treatment of mental health and substance use disorders.

Veterans

H.R.2623 - Innovative Therapies Centers of Excellence Act of 2025, S. 4220 - Veterans Health Administration Novel Therapeutics Preparedness Act.

 Bills named in this filing 3
  • H.R. 7148
    Medicare Home Health Accessibility Act
  • H.R. 2623
    Innovative Therapies Centers of Excellence Act of 2025
  • S. 4220
    Veterans Health Administration Novel Therapeutics Preparedness Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem